Welcome to Roivant

Reinventing the discovery, development, and commercialization of new medicines

About Us

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Learn about us

positive Phase 3 trials since 2019

FDA approvals

Our companies

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization.

Learn about our companies

Immunovant

Advancing potentially transformative therapies for autoimmune diseases

Priovant

Developing targeted therapies for patients with severe autoimmune disease

Pulmovant

Committed to transforming the lives of patients with pulmonary diseases

Roivant Overview - JP Morgan Healthcare Conference 2024

News and Press Releases

Read the latest from Roivant and the media.

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Read the full article here

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at close compared to their respective market opening prices on the day of the announcement.

Organon to Acquire Roivant’s Dermatology Subsidiary for Up to $1.2B

Read the full article here

Organon has announced its plans to acquire Dermavant Sciences, a Roivant company focused on innovative immuno-dermatology treatments. The deal, which is expected to be finalized in the fourth quarter of 2024, will allow Organon to expand its dermatology offerings in the U.S. market, particularly with Dermavant’s flagship product, VTAMA (tapinarof) cream, 1%. VTAMA cream, a novel, non-steroidal topical therapy, was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults.

Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion

Read the full article here

Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. Organon is buying Roivant subsidiary Dermavant and its topical treatment Vtama. The drug is currently approved to treat various forms of the skin condition plaque psoriasis. But analysts and Organon see the real potential in Dermavant’s standing application with the Food and Drug Administration to expand the drug’s label to include atopic dermatitis, another chronic skin condition that affects around 25 million children and adults in the U.S.

Benzinga | Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Read the full article here

Organon & Co has agreed to acquire Roivant Sciences Ltd’s Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology. Dermavant’s novel product, Vtama (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the FDA in May 2022. Vtama cream is a once-daily, steroid-free, topical therapy applied to affected areas.

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

Read the full article here

Roivant is once again reaping the benefits of its bespoke business model. This time, it’s selling Dermavant to Organon for up to $1.2 billion. Most of that money — $950 million — is available via commercial milestones, according to Wednesday’s announcement. Organon is paying $175 million upfront plus another $75 million if Dermavant’s skin cream Vtama snags FDA approval to treat atopic dermatitis, a decision that’s expected by the end of the year. It will also pay tiered royalties on sales to Dermavant shareholders.

For Investors

Learn more about our work

Pipeline

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.